Circulating Tumor Cells and Circulating Tumor DNA

Annual Review of Medicine - Tập 63 Số 1 - Trang 199-215 - 2012
Catherine Alix‐Panabières1,2,3, Heidi Schwarzenbach4, Klaus Pantel4
1University Institute of Clinical Research UM1 – EA2415 – Epidemiology, Biostatistics & Public Health;
2University Medical Center, Laboratory of Cell and Hormonal Biology, Arnaud de Villeneuve Hospital, Montpellier, France;
3University Medical Center, Saint-Eloi Hospital, Institute of Research in Biotherapy, Laboratory of Rare Human Circulating Cells, Montpellier, France;
4Institute of Tumor Biology, University Medical Center, Hamburg-Eppendorf, 20246 Hamburg, Germany;

Tóm tắt

Solid tumors derived from epithelial tissues (carcinomas) are responsible for 90% of all new cancers in Europe, and the main four tumor entities are breast, prostate, lung, and colon cancer. Present tumor staging is mainly based on local tumor extension, metastatic lymph node involvement, and evidence of overt distant metastasis obtained by imaging technologies. However, these staging procedures are not sensitive enough to detect early tumor cell dissemination as a key event in tumor progression. Many teams have therefore focused on the development of sensitive assays that allow the specific detection of single tumor cells or small amounts of cell-free tumor DNA in the peripheral blood of cancer patients. These methods allow the detection and characterization of early metastatic spread and will provide unique insights into the biology of metastatic progression of human tumors, including the effects of therapeutic interventions.

Từ khóa


Tài liệu tham khảo

10.1038/nrc2375

10.1016/j.cell.2011.02.013

10.1038/nrc2256

10.1038/nrclinonc.2009.44

10.1016/j.cell.2009.11.025

10.1186/bcr2561

10.1038/nrc1370

10.1038/nrc3066

10.1038/nrg2540

10.1016/S0002-9440(10)64706-2

10.1016/j.humpath.2006.01.026

10.1007/s10544-010-9485-3

10.1016/j.bios.2010.07.054

10.1039/c0lc00633e

10.1039/c0lc00345j

10.1002/elps.200800373

17. Andreopoulou E, Yang LY, Rangel KM, et al. 2011. Comparison of assay methods for detection of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system.Int. J. Cancer.Epub ahead of print

10.1002/ijc.25819

10.1038/nature06385

10.1056/NEJMoa0800668

10.1126/scitranslmed.3000403

10.1073/pnas.1012539107

10.1073/pnas.1001515107

10.1021/ac103172y

10.1073/pnas.0813188106

10.1007/978-1-61779-052-2_10

10.1200/JCO.2007.13.6523

10.1016/j.ejca.2010.02.038

10.1038/472273a

10.1016/j.cell.2008.03.027

10.1038/nrclinonc.2010.171

32. Mego M, Mani SA, Lee BN, et al. 2011. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy.Int. J. Cancer.Epub ahead of print

10.1016/j.ajpath.2010.12.003

10.1111/j.1582-4934.2011.01285.x

10.1007/s10549-011-1373-x

10.3109/0284186X.2010.549151

10.1002/ijc.24814

10.1038/nnano.2009.333

10.1186/bcr2326

10.1373/clinchem.2006.079509

10.1073/pnas.0404036101

10.1007/s10549-011-1508-0

10.1038/sj.bjc.6604545

10.1186/bcr2131

10.1002/cyto.a.21024

10.1373/clinchem.2010.154328

Agrawal B, 1998, Cancer Res., 58, 4079

10.1172/JCI57229

10.1172/JCI43414

10.1007/s10549-006-9279-8

10.1007/s10585-007-9099-1

10.1158/0008-5472.CAN-06-3940

10.1016/j.canlet.2008.12.007

10.1158/0008-5472.CAN-08-3667

10.1002/cyto.a.20718

10.1158/1078-0432.CCR-06-2701

10.1158/1078-0432.CCR-08-2036

10.1373/clinchem.2010.143297

10.1158/0008-5472.CAN-05-4003

10.1158/1078-0432.CCR-07-0024

10.1186/bcr2333

10.1016/j.canlet.2009.06.027

10.1111/j.1524-4741.2010.00910.x

Gazzaniga P, 2010, Int. J. Cancer, 126, 2437, 10.1002/ijc.24953

10.1056/NEJMoa040766

10.1200/JCO.2007.15.8923

10.1158/1078-0432.CCR-07-0268

10.1158/1078-0432.CCR-08-0872

10.1158/1078-0432.CCR-07-1506

10.1200/JCO.2008.20.6664

10.1158/1078-0432.CCR-05-2821

10.1158/1078-0432.CCR-05-1769

10.1200/JCO.2008.19.4423

74. National Cancer Institute. 2011. Treatment decision making based on blood levels of tumor cells in women with metastatic breast cancer receiving chemotherapy. SWOG-S0500.http://clinicaltrials.gov/ct2/show/NCT00382018

10.1093/annonc/mdp391

10.1158/1078-0432.CCR-09-2042

10.1200/JCO.2009.25.9937

10.1200/JCO.2008.18.0497

10.1158/1078-0432.CCR-04-2469

10.1093/jnci/85.17.1419

10.1002/ijc.24916

10.1016/j.molmed.2010.07.001

10.1038/nrc2627

10.1186/bcr2349

Braun S, 2001, Cancer Res., 61, 1890

10.1007/s10549-010-1163-x

10.1158/0008-5472.CAN-05-4198

Matuschek C, 2010, Eur. J. Med. Res., 15, 277, 10.1186/2047-783X-15-7-277

10.1002/ijc.20240

10.1158/1078-0432.CCR-08-1910

10.2217/bmm.10.118

10.1038/sj.bjc.6605013

10.1200/JCO.2010.34.0026

Thông tin
Thông tin xuất bản

Annual Review of Medicine

Tập 63 Số 1

199-215

Thông tin tác giả